McMaster University

McMaster University



Kjetil Ask

Kjetil Ask, PhD

Associate Member
Biochemistry and Biomedical Sciences

Assistant Professor, Medicine

Firestone Institute for Respiratory Health
50 Charlton Ave. E. - T2112
Hamilton, ON L8N 4A6

905-522-1155 ext. 35355

Visit Kjetil Ask's Homepage


Protein misfolding events have over the past 20 years been associated with the pathogenesis of multiple diseases, ranging from diseases of genetic origins (Cystic Fibrosis/1-Alpha Antitrypsin Deficiency) to metabolic disorders (Diabetes) and Cancer. We are interested to learn more about the molecular events that occur when proteins are not folded correctly in the endoplasmic reticulum (ER) and to elucidate the downstream activation of the Unfolded Protein Response (UPR) to clarify its possible role in disease initiation and progression. Our primary interest is related to events implicated in the initiation and progression of chronic lung disease. We believe that increased understanding of molecular pathways related to protein misfolding will yield novel targets and offer the possibility for future therapeutic modulation of so far untreatable chronic lung diseases.

Academic interests:

The McMaster Demystifying Medicine Seminar Series includes presentations of patients, pathology, diagnosis and therapy in the context of major diseases and current research. This translational seminar series is designed to help increase the understanding of how advances in biochemistry and biology can be applied to human disease. It is directed towards undergraduate and graduate students, post-doctoral fellows and researchers, medical students and clinicians. Please see more information at Demystifying Medicine Seminar Series.

Selected publications

  • Wei J, Rahman S, Ayaub E, Dickhout JG,Ask K. Protein Misfolding in Chronic Lung Disease. Chest, 2013 Apr 1; 143(4):1098-105.PMID: 23546482
  • Hirota JA,Ask K, Farkas L, Smith JA, Ellis R, Rodriguez-Lecompte JC, Kolb M, Inman MD: In vivo role of platelet-derived growth factor-BB in airway smooth muscle proliferation in mouse lung. Am J Resp Cell Mol Biol 2011, 45:566-572.PMID: 21216974
  • Ask K, Eickelberg O, Gauldie J, Kaminski N, Kolb M. Have advanced research technologies made real impact on respiratory medicine? Respirology. 15(6):876-80. 2010.PMID:20646243
  • Moeller A, Gilpin S,Ask K, Cox G, Cook DJ, Gauldie J, Margetts PJ, Farkas L, Dobranowski J, Boylan C, O’Byrne PM, Strieter R and Kolb MRJ. Circulating Fibrocytes Are an Indicator for Poor Prognosis in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 179:588-94, 2009.PMID:19151190
  • Ask K, Moeller A, Farncombe T, Labiris R, Kolb M. The use of small animal imaging in respiratory drug discovery. Drug Discovery Today. Therapeutic Strategies; 5-2, 2008. [external link]
  • Ask K, Labiris RN, Farkas L, Moeller A, Froese AR, Farnecombe T, McClelland G, Inman MD, Gauldie J and Kolb M. Comparison between conventional and clinical assessment of experimental lung fibrosis. J Transl Med. Apr 10; 6:16, 2008:PMID:18402687
  • Ask K, Bonniaud P, Nejman B, Maass K, Eickelberg O, Margetts PJ, Waburton D, Groffen J, Gauldie J and Kolb M. Progressive pulmonary fibrosis is mediated by TGF-beta isoform 1 but not TGF-beta 3. Int J Biochem Cell Biol; 40:484-495, 2008.PMID:17931953
  • Moeller A,Ask K, Gauldie J and Kolb M. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol. 40:362-382, 2008.PMID:17936056
  • Ask K, Martin GEM, Bonniaud P, Kolb M and Gauldie J. Strategies Targeting Fibrosis in Pulmonary Disease. Drug Discovery Today: Therapeutic Strategies. 3(3): 389-394, 2006.[External link]
  • Ask K, Martin GEM, Kolb M and Gauldie J. Targeting Genes for Treatment in Idiopathic Pulmonary Fibrosis: Challenges and Opportunities, Promises and Pitfalls. Proc Am Thorac Soc. 3:389-93, 2006.PMID:16738206
  • Ask K, Décologne N, Ginies C, Låg M, Boucher J-L, Holme JA, Pelczar H and Camus P. Nilutamide metabolism in rat lung. Biochem Pharmacol. 71(3):377-85, 2006.PMID:16313887
  • Ask K, Décologne N. Asare N, Pelczar H, Artur Y and Camus P. Metabolic activation of nilutamide and distribution of nitroreductase activity in rats. Tox Appl Pharmacol. 15;201(1):1-9, 2004.PMID:15519603
  • Ask K, Dijols S, Giroud C, Casse L, Frapart Y-M, Sari M-A, Kim K-S, Stuehr DJ, Mansuy D, Camus P and Boucher J-L. Reduction of the nitroaromatic antiandrogen nilutamide by NO synthases. Implications for the adverse effects of this antiandrogen drug. Chem Res Toxicol. 16(12):1547-54, 2003.PMID:14690368
Valid XHTML 1.0 Transitional Level Double-A conformance, W3C WAI Web Content Accessibility Guidelines 2.0